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1. Introduction 
Encephalitis may be defined as “An acute inflammatory global neurologic dysfunction”, 
characterized by altered mental status with protracted clinical course and high risk of 
significant morbidity. Timely therapeutic intervention is paramount to insure a good 
outcome”. The most common endemic infectious encephalitis in immune-competent hosts 
involves several types of herpes virus infections, frequently herpes simplex virus (HSV). We 
may add to this group the less common epidemic-regional, arbovirus encephalitis. In recent 
years however, identification of novel auto-antibodies lead to the classification of 
autoimmune encephalitis in two clinical settings: 1.A paraneoplastic disorder (PNS) with 
either an overt or an occult neoplasm driving the dysimmune response 2. Antibodies 
directed against specific neuronal receptor channels in patients without underlying 
malignancy. In both groups, the initial management involves search for a possible occult 
neoplasm as a trigger of the autoimmune response and the expeditious initiation of 
immunosuppressive therapy. Autoimmune non-paraneoplastic encephalitis is the focus in 
this chapter. We will discuss four cases with autoimmune encephalitis diagnosed on our 
service in recent years. The clinical phenotype, work up results and treatment will be 
reported. A management algorithm will also be proposed (Figure 1). All four patients were 
residents of either rural or small urban Illinois communities. These cases illustrate how 
familiarity with these disorders and increasing comfort with immune-suppression represent 
a needed skill in the practice of General Neurology. 
2. Case reports 
Case 1  
A 19 year old previously healthy right-handed Caucasian male presented with recent onset 
generalized tonic-clonic seizure on September, 2011. A few days later, he developed 
confusion, automatism, blepharospasm, orofacial dyskinesia and dysautonomia. His pulse 
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rate would vary from 30 to 120 per minute throughout the day. He did not have fever, chills, 
neck stiffness, headache or viral-like prodrome. Neurological examination on admission was 
non-focal. Signs of meningeal irritation or increased intracranial pressure were not present. 
Other than sustained ankle clonus, we did not find additional abnormalities. Initial and 
serial follow-up brain computed tomography (CT) and magnetic resonance imaging (MRI) 
were unremarkable. Cerebrospinal fluid (CSF) findings were non-specific, with a 
lymphocytic pleocytosis (WBC 25, >90% lymphocytes) and negative bacterial, viral, fungal 
and protozoal cultures. Herpes simplex virus polymerase chain reaction (HSV-PCR) was 
negative. An electroencephalogram (EEG) showed slowing of background activity in the 
delta range, without epileptiform discharges. Work up for an occult malignancy 
was unrevealing. Computed tomography of the chest, abdomen and pelvis as well as a 
testicular ultrasound were all normal. Tumor markers including alpha 
fetoprotein (AFP) and beta human chorionic gonadotropin (B-hCG) were all negative. An 
autoimmune study performed by the Mayo Clinic laboratory was positive for anti-N-
methyl D-aspartate (NMDA) antibody and negative for other relevant auto-antibodies, in 
particular the anti-Ma antibody. Treatment with intravenous methylprednisolone (MP), 1 
gram (gm) daily for 5 days and a 5-day course of human immunoglobulin (Ig) at 0.4 gm/kg 
daily for 5 days was initiated. This was repeated once weekly for two months, along with 
tapering oral prednisone and a single dose of Rituximab. The patient also began 500 mg 
of mycofenolate twice daily with gradual and eventually complete neurological 
improvement. The patient returned to the spring semester in College and doing well.  
Case 2  
A 61 year old previously healthy right-handed Caucasian female presented with sudden 
episodic involuntary rapid irregular movements and posturing of the right upper extremity, 
facial grimacing and declining short term memory. Physical examination revealed 
intermittent involuntary facial grimacing and right hemiballismus but otherwise 
unremarkable neurologic examination. Her initial basic metabolic panel (BMP) 
demonstrated sodium (Na) of 127 (normal range 137-145 mmol/l) and Chloride (Cl) of 87 
(normal range 98-107 mmol/l) but was otherwise unrevealing. Thyroid stimulating hormone 
(TSH), Vitamin B12 (B12), antinuclear antibody (ANA) and Copper levels were all within 
normal limits. A CT of the head revealed a 3.5 mm right frontal gray and white 
matter hypodensity. Pre and post-contrast brain MRI showed abnormal signal and edema 
involving the right anterior caudate and lentiform nuclei (Figure 1), and the genu and 
anterior limb of the right internal capsule (Figure 1). Electroencephalogram showed diffuse 
background slowing in the theta and delta range without epileptiform discharges. Several 
involuntary hemibalismus events were video-captured and deemed non-epileptic in nature. 
Magnetic resonance angiography (MRA) of the head and neck and trans-thoracic 
echocardiography (TTE) were normal. Hyponatremia normalized with fluid restriction. 
Clinically, symptoms other than short term memory deficits appeared to spontaneously 
resolve. The initial presumed diagnosis was an atypical vascular event. Repeat brain 
imaging as her clinical course seemed to briefly stabilize, demonstrated no change in 
previously noted abnormality. Subsequently, she developed increased agitation, 
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disorientation, confusion, impulsivity, upper extremity chorea along with fecal and urinary 
incontinence. Her serum sodium dropped to 112 meq/ml, hence a 3 % NaCl therapy was 
initiated. Patient continued to decline clinically and required endotracheal intubation. 
Electroencephalogram showed asymmetric diffuse background slowing at the theta and 
delta frequency range, right hemisphere worse than left. A spinal tap showed normal 
opening pressure with normal glucose, protein, cell count, culture, venereal disease research 
laboratory (VDRL), Cryptococcus, IgG/Albumin ratio, myelin basic protein and oligoclonal 
bands. Patient appeared to improve clinically in relation to correction of her serum sodium 
status. She was extubated within a few days of her initial decline. In her case, hyponatremia 
was thought to be secondary to syndrome of inappropriate anti-diuretic hormone secretion 
(SIADH) and responded well to demeclocycline. Neuropsychiatric evaluation 
revealed deficits in concentration and constructional apraxia with delayed memory speed 
and processing. Patient’s behavioral presentation and scores on cognitive testing suggested 
primarily a subcortical dysfunction with relatively intact performance on tests related to 
cortical functioning. Frequent episodes of facial grimacing and automatisms were noted 
during clinical recovery. A repeat EEG captured multiple complex partial seizures 
emanating from the right temporal lobe, therefore anticonvulsant therapy was started. Two 
follow-up brain MRI studies showed resolution of previous lesions, consistent with a 
transient inflammatory process. 
 
Figure 1. Brain MRI in Autoimmune Encephalitis  
Axial T2 and FLAIR MRI of the brain in case 2. High signal intensity is present in the right caudate 
nucleus and adjacent anterior limb of the internal capsule. 
Autoimmune encephalitis was suspected and patient was started on a 7-day course of 
human Ig at 0.4g/kg/24hours and leviteracetam therapy. In the ensuing week, despite 
normal neuroimaging, she suffered from frequent falls, orthostasis, hypothermia and 
bradycardia. Clinical suspicion of autoimmune encephalitis was confirmed by the presence 
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of anti-voltage gated potassium channel antibodies. Computed tomography of the chest, 
abdomen and pelvis were unremarkable for malignancy making the diagnosis autoimmune 
limbic encephalitis most likely etiology. A 5-day course of human Ig at 0.4g/kg/24 hours was 
administered along with 1 gram IV MP. This was later followed by a slow taper of 
prednisone at 60 mg daily. Neurological exam remained non-focal, except for abnormal 
upper extremity movements which were persistent throughout hospitalization. Her 
dysautonomia, cognition and memory improved significantly. She begun tapering oral 
prednisone upon discharge for eight months and is presently back to normal. 
Case 3 
A 65 year old right-handed Caucasian male was admitted for evaluation of brief intermittent 
episodes of dysarthria, emotional lability and bizarre behavior. According to his wife, 
“crying spells” in recent months were not his usual nature. He had been a very healthy 
individual up until a very recent diagnosis of prostate cancer. Neurological examination 
was remarkable for astereognosia without other focal deficits. Mental status examination 
was normal without evidence of previously reported emotional lability. Initial brain MRI 
without contrast was normal. A comprehensive metabolic panel (CMP) requested on 
admission was remarkable for hyponatremia at 130 mmol/l. An EEG demonstrated 
independent epileptiform discharges from bilateral temporal lobes consistent with 
electrographic partial seizures. Oxcarbamazepine therapy was initiated at an oral dose of 
300 mg twice daily with a recommendation to increase oral salt intake. Outpatient 
neuropsychological testing demonstrated prominent memory dysfunction characterized by 
global amnesia and semantic fluency deficiency consistent with left temporal lobe 
dysfunction. Generalized grand mal seizures and post-ictal confusion prompted 
readmission. Hyponatremia worsened at 126mmol/l, thus oxcarbamazepine was switched to 
leviteracetam. Despite the lack of clinical or electrographic seizure recurrence, the patient 
remained confused and disoriented. A repeat pre and post-contrast brain MRI demonstrated 
symmetric high T2 signal intensity involving bilateral mesial temporal lobes consistent with 
limbic encephalitis (Figure 2). Lumbar puncture (LP) revealed normal pressure, along with 
normal glucose and protein. Cells were not present and cytology was negative for malignant 
cells. Cerebrospinal fluid gram stain and cultures were negative. VDRL, HSV- PCR, 
cryptococcal antigen and lyme titers in the CSF were negative. Cerebrospinal fluid 
paraneoplastic panel was positive for neuronal voltage-gated potassium channel antibodies 
(0.60 nmol/l). Full body positron emission tomography (PET) scan was unremarkable for 
malignancy. Five days of MP at 1 gm/day and human Ig therapy at 0.4mg/kg/day were 
administered. Following these interventions, he demonstrated clinical improvement and 
was able to independently perform all activities of daily living. However, he continued to 
demonstrate severe long term memory impairment for nearly two months. He gradually 
improved on monthly human Ig and MP infusion therapy. In addition, he had episodic 
confusion and aphasia which required Video-EEG monitoring. No electrographic 
epileptiform activity was observed but lamotrigine therapy was initiated and maintained 
with successful outcome. Nearly 8 months from initial presentation, patient was noted to 
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have complete resolution of symptoms. EEG and brain MRI returned to normal. 
Simultaneously, prostate cancer was characterized as adenocarcinoma, with a Gleason score 
of 5. He was treated successfully with external beam irradiation with subsequent decrease in 
his prostate specific antigen (PSA) levels. Human Ig and MP therapy was completed within 
a year and later discontinued. Thereafter, neurological and psychiatric examination 
remained normal. 
 
Figure 2. Brain MRI in Limbic Encephalitis  
Axial FLAIR MRI of the brain in case 3.  Areas of increased signal intensity are noted in the hippocampi. 
The right side is slightly thickened.  CSF examination in this patient was normal and the Voltage-gated 
Potassium antibodies were present 
Case 4 
A 37 year old right-handed Caucasian female presented with an acute delirium associated 
with significant psychomotor agitation. Her past medical history was significant for acute 
polyendocrine autoimmune endocrine syndrome type 2 (APS 2) as well as Hashimoto’s 
thyroiditis diagnosed in her early 20’. A few years later, she developed an acute 
autoimmune adrenal failure secondary to anti-21 hydroxylase antibodies (Titer: 27.3 U/ml; 
Normal :< 1 U/ml). Ovarian failure later ensued in her 30’s. Her clinical and HLA picture 
(DR3 and DR4) were all diagnostic of an APS 2. Her neurologic examination was non-focal. 
A brain MRI and CSF were normal except for the presence of 6 white blood cells in the CSF. 
Herpes simplex virus-PCR was negative as well. An EEG demonstrated diffuse, generalized 
delta rhythm. Three years into her illness, a syndrome of recent memory loss occurred and a 
repeat MRI showed bilateral increased signal intensity involving the hippocampi. Anti-
voltage-gated potassium channel (VGPC) antibody titers and a paraneoplastic panel were 
both unremarkable, and thus a diagnosis of recurrent autoimmune limbic encephalitis was 
made. She improved on high-dose MP followed by tapering oral steroids. Patient has done 
well for the last decade on 20 mg of methotrexate weekly. To our knowledge, this is the first 
description of autoimmune encephalitis associated with APS 2. 
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3. Discussion 
The initial presentation of these patients consisted of an acute deterioration of mental status, 
agitation and sensorial changes with either a complex partial and or focal motor 
seizures. While initial dysfunction of the limbic system was seen in only one case, 
subsequent symptoms related to unilateral or bilateral medial temporal lobe dysfunction, 
complex partial seizures and memory loss developed in two additional patients, shortly 
after onset of symptoms. The term limbic was coined by Paul Broca from the Latin word 
meaning ”ring” [26] . He used the word limbic to define structures located within the medial 
temporal lobes and diencephalon, which are involved in the formation and consolidation of 
short term memory. In addition, neurologic findings localized to this area frequently 
involve movement disorders and automatisms. We will review key pathogenic causes of 
autoimmune encephalitis, describe common clinical characteristics and propose a 
management algorithm. 
4. Pathogenesis 
A practical classification of autoimmune encephalitis can be based on pathogenic 
mechanism. In some instances, autoimmunity is triggered by a known or occult neoplasm, 
however in the absence of malignancy, auto-antibodies are directed against intracellular or 
neural membrane receptors. The cause of autoimmunity in non-PNS cases is unclear. 
Antibodies may be directed against intracellular antigens: (anti-Hu and anti-Ma), or 
antibodies against neuronal antigens (VGKC, NMDA receptor and Gamma-amino butyric 
acid (GABA) type b receptors) (1-25). Identification of these antibodies may provide a clue as 
to the possible associated neoplasm. For instance, anti-NMDA encephalitis is frequently 
associated with germ-cell tumors of the ovary and may rarely be seen in men, as was the 
case we reported. Anti-Ma antibodies are often present among patients with germ cell 
tumors of the testis. The anti-Hu is frequently present in small cell lung carcinoma (SCLC). 
Recent autoimmune encephalitis with antibodies against the alpha-amino-3 hydroxi-
isoxazole propionic acid (AMPA) receptor have been reported reported [24]. Practically, the 
entire gamut of known auto-antibodies should be ordered in this group of patients as there 
is significant clinical overlap despite diverse neuronal antigenic targets. Once herpes virus 
encephalitis is ruled out, an investigation with auto-antibodies evaluation and 
immunosuppressive therapy can be initiated (Table 1). Given that reports from the 
immunologic testing usually take anywhere from two to three weeks, treatment should be 
initiated even before a diagnosis is confirmed. The initial therapy consists of high-dose 
intravenous Methyl-prednisolone, 1 gm daily for five days, followed by intravenous human 
Ig, usually at a dose of 0.4 gm/ kg per day for five additional days. Following a definitive 
diagnosis of autoimmune encephalitis, a plan of prolonged immunosuppressive treatment 
may be designed. 
Importantly, Dalmau, et al recently reported serum reactivity to the leucine-rich glioma 
inactivated 1 protein (LGI1) among patients with VGKC antibodies [11,12]. It is 
unclear however, if anti-VGKC antibodies can be used to screen for this syndrome in every 
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case. Hyponatremia is frequent and was found in two of our patients. We did not evaluate 
our patients for LGI1 antibodies because the above article by Dalmau et al was not in print 
when we evaluated these patients. 
The neuropathologic findings in patients with paraneoplastic (PNS) autoimmune 
encephalitis include perivascular and interstitial lymphocytic cuffing, microglial 
proliferation, gliosis and neuronal degeneration. It is likely that non-PNS autoimmune 
encephalitis is associated with similar findings. 
 
Table 1. Algorithm for autoimmune encephalitis 
Algorithm and work up
Autoimmune Encephalitis 
Immune competent patient 
Repeat 
Brain 
MRI 
CSF 
*See list 
Search 
for occult 
neoplasm 
Serum  
Autoanti-
bodies 
*See list 
EEG CSF 
HSV 
PCR 
Serum  
Autoanti
-bodies 
*See list 
EEG Treat 
with 
Acyclovir 
Normal 
Brain MRI
Abnormal 
Brain MRI 
Consider initiation of treatment with 
immunosuppression 
:Methlyprednisolone or iv IG until 
repeat of autoantibodies HSV PCR (+) 
continue treatment 
with Acyclovir 
HSV PCR (-) 
Search for occult 
neoplasm 
Consider initiation of 
treatment with 
immunosuppression 
:Methlyprednisolone 
or iv IG until repeat 
of autoantibodies 
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5. Clinical findings 
The initial clinical manifestations of these disorders may suggest compromise of limbic 
structures and often precede global cerebral dysfunction. This sequence was observed in 
three of our patients (Table 2, cases 2, 3, 4). At times, a more rapid onset of symptoms may 
be observed. (Table2, case 1). Complex partial and Grand mal seizures are both common. 
Focal signs are otherwise infrequent, however confusion, agitation and delirium are present 
and maybe the initial presentation, particularly in anti-NMDA antibody mediated 
encephalitis. HSV encephalitis should be excluded and initiation of acyclovir therapy should 
not be delayed until CSF HSV-PCR result is available. Lack of improvement or worsening 
clinical picture despite treatment with acyclovir may suggest autoimmune encephalitis. 
Nutritional deficiency with Korsakoff’s psychosis is usually evident from additional history 
and clinical findings. It is not possible from the clinical findings alone to determine if 
encephalitis represents a PNS. In fact, in greater than 65% of cases, PNS-related encephalitis 
is the first symptom of cancer. Occasionally, autoimmune encephalitis may mimic 
Creutzfeldt- Jacob disease (CJD) and both serum and CSF neuronal specific enolase, 14:3:3 
protein and tau levels can be elevated. Consequently, a diagnosis of autoimmune 
encephalitis should be considered among possible CJD patients. Brain MRI is often 
abnormal in autoimmune limbic encephalitis; however a normal brain MRI in NMDA-
associated encephalitis is not infrequent. 
6. Neuroimaging 
Brain MRI is generally abnormal. Unilateral or bilateral increased signal abnormalities 
involving mesial temporal lobes may be observed (Figure 2). Thickening of the hippocampi 
may be present without significant mass effect. Contrast enhancement is not frequent. Non-
limbic MRI lesions may be found as well. The presence of susceptibility artifact if found 
would be suggestive of HSV encephalitis. In cases of anti-NMDA receptor encephalitis, 
imaging may be normal, thus making the diagnostic process even a greater challenge. The 
imaging abnormalities described may improve after initiation of treatment. 
7. Additional testing 
A work-up summary for patients with presumed autoimmune encephalitis is suggested in 
table 1. Electroencephalography would be abnormal in most cases. Generalized or focal 
slowing, epileptiform discharges emanating from temporal or frontal lobes are both 
frequent. Status epilepticus would be an unusual finding. Lumbar puncture frequently 
reveals a normal pressure and may show moderate lymphocytosis, increased protein and 
possibly oligoclonal bands, increased IgG and increased CNS IgG synthesis rate. HSV titers 
and PCR should be negative and neuronal specific enolase levels may be increased. Auto-
antibodies may also be detected in CNS and titers can be monitored as a measure of 
treatment response. Comprehensive metabolic panels are generally normal with the 
exception perhaps of hyponatremia due to SIADH. Tumor markers may be present, 
suggesting PNS. We propose a work up algorithm that has been helpful in our experience. 
(table 1) A list of auto-antibodies, including PNS is listed in table 3 
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Patient Clinical 
Presentation 
MRI 
Findings 
CSF 
Findings 
Autoimmune 
Antibodies 
Management 
Case 1  
19-year 
old 
male 
Confusion 
Automatisms 
Oral dyskinesia 
Blepaharospasm 
Dysautonomia 
Normal 
X 2 
Lymphocytic 
Pleocytosis 
25 WBC 
Anti 
NMDA 
Receptor 
Antibodies 
Mp 
Human IG 
Rituximab 
Cellcept 
Case 2 
61 year 
old 
female 
Chorea 
Dystonia 
Hyponatremia 
Agitation 
Confusion 
Increased 
Signal 
Caudate + 
Lentiform 
Nuclei + 
internal 
capsule 
Normal Anti –Voltage 
Gated K 
Channel 
Antibodies 
MP 
Human IG 
Oral 
Prednisone 
Case 3 
65 year 
old male 
Anxiety 
Crying spells 
Personality 
Change 
Hyponatremia 
Memory Loss 
Partial complex 
and grand mal 
seizures 
Increased 
signal in 
bilateral 
temporal 
lobes 
Normal Anti-Voltage 
Gated K 
Channel 
Antibodies 
MP 
Monthly 
Human IG 
Case 4 Agitation 
Confusion 
Memory Loss 
Partial Complex 
seizures 
Increased 
Signal 
bilateral 
temporal 
lobes 
Mild CSF 
Lymphocytosis  
6 WBC 
Increased 
Lactic Acid 
One OCB* 
Anti-
microsomal 
antibodies 
Antibodies 
against the 21- 
hydroxilase 
Polyendocrine 
Autoimmune 
failure  type 2 
MP 
Human IG 
Weekly 
Methotrexate 
Oral 
prednisone 
Table 2. Clinical presentation, pertinent work-up and management of four cases 
Neuronal Nuclear Antibodies 
Antineuronal Nuclear Antibody- Type 1 (ANNA-1) 
Antineuronal Nuclear Antibody- Type 2 (ANNA-2) 
Antineuronal Nuclear Antibody- Type 3 (ANNA-3) 
Neuronal and Muscle Cytoplasmic Antibodies 
Purkinke Cell Cytoplasmic Antibody- Type 1 (PCA-1) 
Purkinke Cell Cytoplasmic Antibody- Type 2 (PCA-2) 
Purkinke Cell Cytoplasmic Antibody- Type Tr (PCA-Tr) 
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Amphiphysin Antibody 
CRMP-5-IgG 
Cation Channel Antibodies 
N-Type Calcium Channel Antibody 
P/Q Type Calcium Channel Antibody 
Acetylcholine Receptor (Muscle) Binding Antibody 
Acetylcholine Receptor Ganglionic Neuronal Antibody 
Paraneoplastic Evaluation Algorithm 
Aliases: 
Acetylcholine Receptor (Muscle AChR) Binding Antibody 
AChR (Acetylcholine Receptor) 
AGNA 
Amphiphysin Antibody, serum 
ANNA (Antineuronal Nuclear Antibody) 
AntiCV2 
Anti-Enteric Neuronal Antibody 
Anti-GAD65 (Anti-Glutamic Acid decarboxylase) 
Anti-Glial Nuclear Antibody 
Anti-Purkinke Cell Cytoplasmic Antibody 
Anti-Ri 
Anti-Skeletal Muscle Antibody 
Anti-Yo 
Antineuronal 
APCA (Anti-Purkinke Cell Antibody 
Calcium Channel Blockers 
Cantoxin (Receptor Antibodies) 
Cerebellar Antibodies 
Syndrome and Antibody 
Chorea 
Collapsin Response-Mediator Protein 5 Antibody (CRMP-5), serum 
Cramp-Fasciculation 
CRMP-5-IgG 
Dorsal Root Ganglion Antibody 
Hu Antibody 
ICab (Islet Cell Cytoplasmic Antibody) 
 
Isaac’s disease 
Motor End-Plate Antibody 
Motor Nerve Terminal Antibodies 
Muscle Skeletal Antibodies 
Muscle Culture Antibodies 
Myoid Antibody 
N-Type Calcium Channel Antibody 
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Neuromuscular hyperexcitability 
Neuromyotonia 
Neuronal Ganglionic Acetylcholine Receptor Antibody 
Neuronal Nuclear Antibody 
Neuronal Nuclear Antibody Panel 
NMDA-Receptor Antibody (N-Methyl-D-Aspartate Receptor Antibodies) 
Ovarian Cancer-Related Antibodies 
P/Q Type Calcium Channel Antibody 
Paraneoplastic Antibodies 
Paraneoplastic Autoantibody Evaluation 
Paraneoplastic Neurological Autoimmunity 
Purkinke Cell Cytoplasmic Antibody- Type 1 (PCA-1) 
Purkinke Cell Cytoplasmic Antibody- Type 2 (PCA-2) 
Purkinke Cell Cytoplasmic Antibody- Type Tr (PCA-Tr) 
Potassium Channel Antibodies (specify) 
Ri, Antibody 
Stiff-man Syndrome 
Glutamic Acid Decarboxylase Antibody (Gad 65) 
Striational (Striated Muscle) Antibodies 
VGCC (Volatage Gated Calcium Channel Antibody) 
Eaton Lambert Syndrome 
Yo-Antibody 
Ovarian Cancer 
Table 3. Antibody testing among patients with autoimmune neurologic syndromes 
8. Treatment 
There is no evidence-based data to guide management of autoimmune encephalitis. Initially, a 
combination of intravenous high dose MP for 5 days and human Ig dose of 0.4 gm/kg for 5 
days can be the first line of treatment. This may be followed by monthly injection of MP and 
human Ig. Rituximab may be helpful with 4 to 6 monthly doses. In some cases, additional on-
going immunosuppression with mycofenolate or cyclophosphamide may be needed to treat 
either slow or non-improving cases. In addition, if the work up uncovers a neoplasm, surgical 
resection or chemotherapy should be initiated without delay. Considering that the initial 
identification of non-PNS autoimmune encephalitis is relatively recent, epidemiologic factors 
are now becoming apparent. Frequency and geographic distribution of these disorders will be 
available soon and this information could set the stage for future multicenter treatment trials.  
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